Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]
In development
Reference number: GID-TA11439
Expected publication date: TBC
Pending further discussion with the company, the timelines for this appraisal are now to be confirmed. We are unable to provide a revised timeline at this time as the company is currently evaluating its plans for a submission.
Submissions are no longer required by 3 December 2025, and the committee meeting scheduled for 12 May 2026 will not take place. We will write to you when a new submission deadline and updated timelines are confirmed.